Home > Healthcare > Pharmaceuticals > Finished Drug Form > Dyspepsia Drugs Market

Dyspepsia Drugs Market Trends

Report ID: GMI7670
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Dyspepsia Drugs Market Trends

Dyspepsia is often associated with aging, and its prevalence tends to rise in older populations. Age-related changes in the digestive system, such as reduced stomach acid secretion and changes in gastric motility, can contribute to the development of dyspeptic symptoms. Thus, the increasing demand and utilization of dyspepsia drugs among aging population is expected to support the growth of this market.
Further, over-the-counter drugs, including antacids and PPIs, offer consumers the flexibility to address these symptoms proactively. Therefore, accessibility and availability of OTC dyspepsia drugs in retail pharmacies setting contribute to market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Dyspepsia drugs industry size accounted for USD 9.7 billion in 2023 and is set to register 4.5% CAGR to reach USD 14.3 billion by 2032 driven by increasing prevalence of dyspepsia, growing aging population, and rising preference for over the counter (OTC) drugs/medications.

The functional dyspepsia segment accounted for USD 6.9 billion in 2023 and poised to grow at a swift pace through 2032 owing to its high prevalence.

North America dyspepsia drugs industry will reach USD 6.1 billion by 2032 with CAGR of 4.4% over the next decade driven by high prevalence of dyspepsia, alongside a higher incidence of gastroesophageal reflux disease (GERD).

Takeda Pharmaceutical Company Limited, AstraZeneca plc, Salix Pharmaceuticals, Inc., Abbott Laboratories are some of the major industry contenders.